PubMed Açık Erişimli Yayınlar

Permanent URI for this collectionhttps://hdl.handle.net/11727/10763

Browse

Filters

2020 - 20224

Settings

Author: search.filters.author.Esin, Sertac

Search Results

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Associations between IL-1 alpha, IL-1 beta, TNF alpha, and IL-6 variations, and susceptibility to transposition of the great arteries
    (2022) Atasoy Karakas, Latife; Tugrul, Duygu; Sahin Uysal, Nihal; Esin, Sertac; Tokel, Niyazi Kursat; Terzi, Yunus Kasim; 35590253; AEY-5060-2022
    Background: To evaluate the relationship between IL-1 alpha-889UT (rs1800587), IL-1 beta -511 C >T (rs16944), TNF alpha-308G > A (rs1800629), TNF alpha-238G > A (rs361525), IL-6 -174G> C (rs1800795), and IL-6 -572G > C (rs1800796) polymorphisms and the susceptibility to transposition of the great arteries (TGA). Methods: A prospective analysis was performed on mothers whose newborns were diagnosed as having TGA. For each case of TGA, a mother who gave birth to a healthy neonate in the same period was randomly selected for the control group. The sample size was calculated before planning the study with 80% power and 5% alpha. Results: Twenty-seven mothers whose newborn had TGA anomalies (group 1) and 27 mothers whose newborn had no TGA (group 2) were included in the study. There were no significant differences between the groups in terms of maternal age, pregestational body mass index, gestational age at birth and infant sex (p> 0.05). The genotype and allele distributions of IL-1 alpha -889C/T (rs1800587), IL-1 beta -511C >T (rs16944), TNF alpha -308G >A (rs1800629), TNF alpha -238G > A (rs361525), IL-6 -174G> C (rs1800795) and IL-6 -572G > C (rs1800796) gene variants were not different between the two groups (p> 0.05). Conclusions: There was no relation between IL-1 alpha, IL-1 beta, IL-6, and TNF alpha promoter gene polymorphisms and TGA occurrence in our study group.
  • No Thumbnail Available
    Item
    sRepeated Dose of Prostaglandin E2 Vaginal Insert When the First Dose Fails
    (2021) Karadag, Ceyda; Esin, Sertac; Tohma, Yusuf Aytac; Yalvac, Ethem Serdar; Basar, Tugrul; Karadag, Burak; 0000-0001-9418-4733; 33715333; AAE-6482-2021
    Objective: To compare the obstetric and neonatal outcomes of patients treated with repeated-dose prostaglandin E2 (dinoprostone) vaginal insert when the first dose fails. Materials and Methods: This retrospective study included 1.043 pregnant women who received dinoprostone for labor induction between November 2012 and August 2015. Pregnant women were divided into two groups according to the number of dinoprostone administrations: group 1, single-dose dinoprostone (n=1.000), and group 2, repeated-dose dinoprostone (n=43). Intrapartum, postpartum, and neonatal outcomes of the pregnant women were compared. Results: Vaginal delivery rate was 65% in group 1 and 30.2% in group 2 (p=0.001). The need for the neonatal intensive care unit was found in 44 pregnant women (4.4%) in group 1 and 6 pregnant women (13.6%) in group 2 (p=0.006). Conclusion: When obstetric and neonatal data were evaluated in our study, we observed that dinoprostone administration was associated with increased cesarean rates and adverse neonatal outcomes with repeated-dose dinoprostone when the first dose failed.
  • No Thumbnail Available
    Item
    Clinical management of coronavirus disease 2019 (COVID-19) in pregnancy: recommendations of WAPM-World Association of Perinatal Medicine
    (2020) Api, Olus; Sen, Cihat; Debska, Marzena; Saccone, Gabriele; D'Antonio, Francesco; Volpe, Nicola; Yayla, Murat; Esin, Sertac; Turan, Sifa; Kurjak, Asim; Chervenak, Frank; 0000-0001-9577-4946; 32692708; AAI-8810-2021
    These guidelines follow the mission of the World Association of Perinatal Medicine, which brings together groups and individuals throughout the world with the goal of improving outcomes of maternal, fetal and neonatal (perinatal) patients. Guidelines for auditing, evaluation, and clinical care in perinatal medicine enable physicians diagnose, treat and follow-up of COVID-19-exposed pregnant women. These guidelines are based on quality evidence in the peer review literature as well as the experience of perinatal expert throughout the world. Physicians are advised to apply these guidelines to the local realities which they face. We plan to update these guidelines as new evidence become available.
  • No Thumbnail Available
    Item
    Risk factors for sexual dysfunction in pregnant women during the COVID-19 pandemic
    (2020) Karakas, Latife A.; Azemi, Asli; Simsek, Seda Y.; Akilli, Huseyin; Esin, Sertac; 0000-0001-9577-4946; 0000-0001-7369-5470; 33141928; AAI-8810-2021; AAI-8793-2021
    Objective To evaluate the level of sexual function during the COVID-19 pandemic in pregnant women followed up in Baskent University Faculty of Medicine, Turkey, using the Female Sexual Function Index (FSFI). Methods An observational analysis was performed on pregnant women who were not infected with COVID-19. A total of 135 pregnant women (group 1), 45 of whom were in the first trimester, 45 in the second trimester, and 45 in the third trimester, and 45 healthy women who were not pregnant (group 2), were included in the study. The FSFI was used to assess sexual dysfunction status. Results A total of 118 (87.4%) pregnant participants and 31 (68.9%) non-pregnant participants were diagnosed as having sexual dysfunction according to the FSFI. When comparing groups 1 and 2, FSFI scores were significantly lower in group 1 (p = 0.002). It was also found that women who had university degrees, were multiparous, and in the third trimester were more likely to develop sexual dysfunction (p = 0.030, p = 0.029, and p = 0.001, respectively). FSFI scores were found to be significantly higher in planned pregnancies than in unplanned pregnancies (p = 0.001). Conclusion The sexual function of uninfected pregnant women decreased during the COVID-19 pandemic, negatively influenced by restrictive social distancing measures.